Genetic engineering of T cells for adoptive immunotherapy in cancer patients has shown significant promise. To ensure optimal antitumor activity and safety, the simultaneous expression of multiple genes is frequently required, and short viral-derived 2A sequences are increasingly preferred for this purpose. Concerns exist, however, that these virus-derived sequences may induce unwanted immune responses, and thus diminish persistence of the gene-modified cells after adoptive transfer. Whereas such responses were absent in immunocompromised recipients, potential immunogenicity in immunocompetent individuals remains a concern. We now address whether ex vivo T cell responses can be elicited against the most widely used 2A sequences (2A-Thosea asigna virus (TAV) or 2A-equine rhinitis virus (ERAV), specifically) in immunocompetent individuals. We used a potent ex vivo culture system previously validated to induce T cell responses even against weakly immunogenic antigens. Of the sixteen donors tested, only five released very low levels of interferon-g in response to 2A-TAV peptide mixtures (single peptide specificity in three donors, adjacent self-antigen peptide specificity in one donor and nonspecific reactivity in one donor). None of them produced cytotoxic activity or responded to 2A-ERAV. These results suggest that exposure to viral-derived 2A sequences is unlikely to produce unwanted T cell responses in immunocompetent individuals and further supports their continued use for studies of human gene therapy.
INTRODUCTION
Adoptive T cell-based immunotherapies and vaccines are promising approaches for cancer patients, and genetic engineering can significantly improve their potency.
1,2 Efficient expression of multiple genes in one single polycistronic vector can simultaneously coordinate the expression of multiple components of the immune system against cancer cells and counterbalance tumor immune evasion mechanisms, 3 and is often critical for the success of these therapies. For example, production of T lymphocytes that will safely and efficiently kill tumor cells after adoptive transfer may require simultaneous genetic modifications to increase their tumor specificity by forced expression of engineered T cell receptors; 2, 4 enhance their trafficking by expression of chemokine receptors; 4, 5 prolong their persistence by forced expression of cytokines or co-stimulatory molecules [6] [7] [8] [9] [10] [11] and augment safety by the incorporation of a suicide switch to remove gene-modified cells on demand. 12, 13 Of the available strategies to generate polycistronic vectors, virus-derived 2A sequences are one of the most effective.
14 These sequences are cis-acting hydrolase elements that mediate a ribosomal skip between 2A-linked genes, 15 resulting in stoichiometric protein production 16 that can improve transgene expression and function, for example, of T cells engineered with transgenic abT cell receptors. 17 Moreover, 2A sequences are quite short (54-60 nucleotides), and therefore have little impact on vector-packaging limits. However, as the 2A sequences are of viral origin, their expression in fusion proteins could lead to the expression of immunogenic epitopes and thereby diminish the in vivo persistence of corresponding gene-modified cells.
Recently, 2A sequences have been successfully incorporated in vectors used in human studies without eliciting discernible immune responses, although the recipients in these trials were significantly immunocompromised. 13, 17 Thus, to discover whether virus-derived 2A sequences may cause troublesome immunogenicity in immunocompetent individuals, we assessed if T cell responses could be elicited to protein regions derived from two vectors containing either the 2A-TAV (Those asigna virusderived) 13 or the 2A-ERAV (equine rhinitis virus-derived) 7 sequences. We used a potent ex vivo culture system that has been previously optimized to expand T cells with specificity for weak antigens, even from antigenically naive individuals, 18 such as umbilical cord blood T cells. 19 Our results support the continued exploration of 2A sequences even in immunocompetent human subjects.
RESULTS AND DISCUSSION
Using our optimized culture system, [18] [19] [20] we successfully generated T cell lines from normal adult donors that had robust interferon-g (IFN-g) production in response to the cytomegalovirus-derived pp65 peptide mixture (pepmix) (1274.6±91.9 IFN-g spot-forming cells (SFCs) per 10 5 cells) in 7/7 donors ( Figure 1a ) and to the weak tumor-associated antigen, preferentially expressed antigen of melanoma (PRAME) pepmix 18 (409.1±29.7 IFN-g SFCs per 10 5 cells) in 8/9 donors (Figure 1b) . By contrast, when we used the same culture conditions with peptide mixtures derived from the two 2A sequences, we found minimal reactivity against the 2A-TAV pepmix in only 5 of the 16 donors tested (59.6±6.7 IFN-g SFCs per 10 5 cells) (Figure 1c) , and no discernible responses against the 2A-ERAV-pepmix in any of the 11 donors tested (Figure 1d) Figure 2 ). To identify the weakly immunogenic peptides derived from the 2A-TAV sequence, we tested each of the 11 single 15-mer peptides against the five weakly reactive T cell lines. Three of these five lines (derived from donor nos. 13, 14 and 15, Figure 3a ) released IFN-g upon exposure to the RAEGRGSLLTCGDVE peptide (51.9 ± 6.9 IFN-g SFCs per 10 5 cells, peptide no. 5 of the pool, Figure 4a ). The line from donor no. 9 ( Figure 3a Figure 4a ). These are junctional peptides between the 2A sequence, and the carboxyand amino-terminal sequences of the expressed genes of interest (human inducible caspase9 and the signal peptide sequence of human CD19, respectively). The line derived from donor no. 8 was responsive against the 2A-TAV pepmix, but had no discernible reactivity to any of the individual peptides contained in the mixture and was thus classified as nonspecific.
To discover the associated biological consequences of the lowlevel IFN-g responses seen in the four antigen-specific T cell lines, we measured their cytotoxic properties using the CD107a/b degranulation assay. All these lines responded appropriately to polyclonal stimulation with phorbol myristate acetate and (Figures 1c and 3a) . As expected, pp65-specific-and PRAME-reactive lines specifically degranulated on exposure to the corresponding pp65 or PRAME pepmixes (13.3±12.2% þ NK cells. Shown are mean ± s.d. of percentage of positive cells for CMV-pp65 lines (n ¼ 7, black bars), for PRAME lines (n ¼ 7, white bars), for 2A-TAV lines (n ¼ 14, light gray bars) and for 2A-ERAV lines (n ¼ 9, dark gray bars). We found a trend for a lower proportion of CD8 þ T cells in 2A-TAV and 2A-ERAV lines (P ¼ 0.07) as compared with CMV-pp65 or PRAME lines.
We next assessed whether T cells transduced with the 2A-TAVcontaining retroviral vector, SFG.iCasp9.2A-TAV.DCD19, could present and process any of these epitopes. Autologous T cells from the reactive donor nos. 9, 13, 14 and 15 were transduced (CD3 þ CD19 þ ¼ 53.7±11.5%) (Figure 3d ) and then used as targets in a standard 6-h 51 Chromium (Cr)-release assay. No significant lysis of 2A-TAV transduced (TD) or non-transduced autologous target T cells was observed in any of the donors tested (3.5±2.9% specific lysis against NT, 3.75±3.9% specific lysis against TD T cells, effector to target ratio (E:T) 20:1) (Figure 3e) . Thus, our potent ex vivo culture system shows that the viralderived 2A-TAV and 2A-ERAV ribosomal skip sequences, and adjacent fusion protein regions exhibit very low (n ¼ 5) to absent (n ¼ 11) immunogenicity in 16 healthy donors. That this paucity of response is genuine rather than a reflection of deficiencies in our detection system is demonstrated by the anticipated high level of reactivity against cytomegalovirus-derived antigens (7/7) or weak tumor antigens (8/9), and by our ability to generate an expected low frequency (1/16) of lines weakly reactive with peptides derived from the self-antigens linked by the 2A sequences (human caspase9 and CD19) that were also included in the peptide mixtures. Of note, the three donors with low-level reactivity to the peptide no. 5 of the 2A-TAV sequence (donors no. 13-15) shared the same class-I-restricted human leukocyte antigen (HLA) alleles (HLA-A*02 and HLA-B*44) and certain class-II haplotypes, including HLA-DRB1*04, HLA-DQB1*03 (Table 1 ). These findings suggest that the reactive peptide no. 5 of the SFG.iCasp9.2A-TAV.DCD19 retroviral vector could contain an HLA class-I or class-II epitope presented in the context of either of these HLA molecules. Given the overall low level of reactivity of these lines, we could not further dissect these reactivities, and precisely identify the epitope and its HLA context. The epitope prediction algorithms from SYFPEITHY (http://www.syfpeithi.de/) and the BioInformatics and Molecular Analysis Section, NIH, (http://www-bimas.cit.nih.gov/ molbio/hla_bind/) failed to indicate a significantly highscoring epitope within the 2A-TAV sequence in the context of Figures 3a and 4a) . Nonetheless, 7 of the 11 HLA-A*02 þ donors failed to generate responses against such epitopes.
Adoptive T cell therapy in cancer patients aims to generate a long-term persistence of the transferred gene-modified T cells. This can be undermined if vectors contain potentially immunogenic sequences, and TD cells are infused in immunocompetent individuals or if multiple T cell administrations are performed. In these situations, in vivo sensitization against vector components can be induced and result in the immune-mediated elimination of the TD cells. No ex vivo system can fully reproduce the in vivo situation of a 'booster vaccination' effect, but we have attempted to answer immunogenicity concerns in our in vitro culture system by using three antigen-specific stimulations with professional antigen-presenting cells (dendritic cells) to amplify T cell responses from immunocompetent individuals. No significant cytotoxic activity was observed in the 16 donors tested, although this limited sample size means we cannot exclude a true positive rate of up to 0.17.
Only clinical trials that include these 2A sequences in immunocompetent individuals can definitely address the issue of their immunogenicity. However, the minimal reactivity we observed to the 2A-TAV sequence (in terms of IFN-g production) associated with the lack of cytotoxic activity, as measured by the CD107a/b degranulation, seems unlikely to result in significant biological consequences, particularly as we found no evidence that these peptides could even be naturally processed and presented by T cells. In conclusion, our data suggest that the incorporation of 2A sequences in polycistronic vectors should not precipitate unwanted immune responses against the TD cells. Of the two 2A sequences studied, 2A-ERAV may be even less immunogenic than 2A-TAV. Careful monitoring for potential immunogenicity in future clinical trials with diverse patients and vectors will, however, still be required before we can be certain that there is no effective 2A-directed immune response against the TD T cells. ). The pepmixes or single peptides were used to pulse dendritic cells, as previously described. 18 Pepmixes spanning the cytomegalovirus pp65 protein or the cancer testes antigen PRAME (JPT Peptide Technologies) were used as controls. 18, 20 Generation and expansion of peptide-specific T cell lines Buffy coats from healthy volunteer blood donors were obtained through the Gulf Coast Regional Blood Center, Houston, TX, USA. HLA typing of these samples was performed by the HLA, Flow and Diagnostic Immunology Laboratory of the Department of Laboratory Medicine at The Methodist Hospital, Houston, TX, USA, using PCR-SSO DNA-based procedures. Peripheral blood mononuclear cells were isolated by Lymphoprep (Accurate Chemical and Scientific Corp, Westbury, NY, USA) density gradient centrifugation. Dendritic cells were generated as previously described, 18 starting from CD14-selected cells and, after maturation, pulsed with 5 mM of the specific pepmix for 2 h at 37 1C and finally used to stimulate peripheral blood mononuclear cells at an E:T ratio of 20:1 in complete media, containing 45% Click's media (Irvine Scientific, Santa Ana, CA, USA), 45% RPMI 1640 (HyClone Laboratories, Logan, Utah), 5% heat-inactivated human AB serum (Valley Biomedical, Winchester, VA, USA), 1% L-glutamine and 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA) in the presence of a previously validated combination of cytokines (IL-7 (10 ng ml À 1 ), IL-12 (1 ng ml À 1 ) and IL-15 (2 ng ml À 1 ) (all from Peprotec, Rocky Hill, NJ, USA or R&D Systems, Minneapolis, MN, USA). 18 On days 9 and 16 of culture, T cells were re-stimulated with pepmix-pulsed dendritic cells at an E:T ratio of 10:1 in media containing IL-7, IL-12 and IL-15. IL-2 (50 U ml À 1 ) was added to the culture from day 16. Lack of immunogenicity of viral 2A sequences C Arber et al
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